IndusLaw Advised Tirupati Medicare on ₹1,050 Crore Investment by Kotak Strategic Situations India Fund II

 IndusLaw Advised Tirupati Medicare On ₹1,050 Crore Investment By Kotak Strategic Situations India Fund II

IndusLaw advised Tirupati Medicare Limited on a ₹1,050 crore investment by Kotak Strategic Situations India Fund II and Kotak Alternate Asset Managers Limited. This funding will support Tirupati Medicare’s expansion and is expected to facilitate a complete exit for Affirma Capital, which had invested ₹350 crore in 2019 as a significant minority shareholder.

Founded in 2005, Tirupati Medicare is a leading player in the Pharmaceuticals, Nutraceuticals, Ayurveda, Veterinary, Probiotics, and Sports Nutrition sectors. The company specializes in end-to-end solutions, from research to product launch, with multiple state-of-the-art manufacturing facilities.

The transaction was led by Shantanu Jindel (Partner) and Shweta Gupta (Partner), with support from Mandvi Singh (Senior Associate), Harshit Kumar (Senior Associate), Vatsal Agarwal (Associate), and Abhinav (Associate).

JSA and Quillon Partners also advised on the transaction.